BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ligritinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ligritinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07619313-2317@assetmemo.bio
DTSTAMP:20261121T005450Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ligritinib: Phase 1 readout est. (NCT07619313)
DESCRIPTION:Ligritinib\, phase 1.\nStudy: AB801 in Combination With Chemoth
 erapy and Immunotherapy for the Treatment of Patients With Borderline Rese
 ctable\, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic C
 ancer\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ligritinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07619313
URL:https://assetmemo.bio/drug/ligritinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
